Pegavision Corporation (6491.TW)
TWD 361.5
(-0.14%)
TWD 361.5
(-0.14%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.56 Billion TWD | 53.85% |
| 2022 | 1.01 Billion TWD | 35.43% |
| 2021 | 750.67 Million TWD | 53.39% |
| 2020 | 489.39 Million TWD | 60.6% |
| 2019 | 304.72 Million TWD | -52.99% |
| 2018 | 648.18 Million TWD | 342.95% |
| 2017 | 146.33 Million TWD | 22.36% |
| 2016 | 119.59 Million TWD | -33.71% |
| 2015 | 180.4 Million TWD | 4.52% |
| 2014 | 172.6 Million TWD | -14.57% |
| 2013 | 202.04 Million TWD | 17.06% |
| 2012 | 172.6 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.15 Billion TWD | -26.25% |
| 2024 Q3 | 1.22 Billion TWD | 21.69% |
| 2024 Q2 | 1.06 Billion TWD | -7.59% |
| 2023 Q3 | 1.01 Billion TWD | -15.43% |
| 2023 Q4 | 1.56 Billion TWD | 54.81% |
| 2023 Q1 | 1.13 Billion TWD | 11.55% |
| 2023 FY | 1.56 Billion TWD | 53.85% |
| 2023 Q2 | 1.19 Billion TWD | 5.35% |
| 2022 Q4 | 1.01 Billion TWD | -10.35% |
| 2022 Q1 | 962.05 Million TWD | 28.16% |
| 2022 Q2 | 1.36 Billion TWD | 41.92% |
| 2022 FY | 1.01 Billion TWD | 35.43% |
| 2022 Q3 | 1.13 Billion TWD | -16.95% |
| 2021 Q2 | 458.14 Million TWD | 5.31% |
| 2021 Q1 | 435.03 Million TWD | -11.11% |
| 2021 Q3 | 690.68 Million TWD | 50.76% |
| 2021 Q4 | 750.67 Million TWD | 8.69% |
| 2021 FY | 750.67 Million TWD | 53.39% |
| 2020 FY | 489.39 Million TWD | 60.6% |
| 2020 Q4 | 489.39 Million TWD | 25.03% |
| 2020 Q1 | 262.8 Million TWD | -13.76% |
| 2020 Q2 | 310.79 Million TWD | 18.26% |
| 2020 Q3 | 391.41 Million TWD | 25.94% |
| 2019 Q1 | - TWD | -100.0% |
| 2019 FY | 304.72 Million TWD | -52.99% |
| 2019 Q4 | 304.72 Million TWD | -83.09% |
| 2019 Q3 | 1.8 Billion TWD | 12.43% |
| 2019 Q2 | 1.6 Billion TWD | 0.0% |
| 2018 Q2 | 858.57 Million TWD | 0.0% |
| 2018 Q1 | - TWD | -100.0% |
| 2018 FY | 648.18 Million TWD | 342.95% |
| 2018 Q4 | 648.18 Million TWD | 0.0% |
| 2017 Q1 | 160.92 Million TWD | 34.55% |
| 2017 FY | 146.33 Million TWD | 22.36% |
| 2017 Q3 | 197.83 Million TWD | 91.97% |
| 2017 Q2 | 103.05 Million TWD | -35.96% |
| 2017 Q4 | 146.33 Million TWD | -26.04% |
| 2016 FY | 119.59 Million TWD | -33.71% |
| 2016 Q4 | 119.59 Million TWD | -31.56% |
| 2016 Q3 | 174.75 Million TWD | 23.8% |
| 2016 Q1 | 222.15 Million TWD | 23.14% |
| 2016 Q2 | 141.15 Million TWD | -36.46% |
| 2015 Q4 | 180.4 Million TWD | -33.54% |
| 2015 Q2 | 188.88 Million TWD | -34.02% |
| 2015 FY | 180.4 Million TWD | 4.52% |
| 2015 Q3 | 271.45 Million TWD | 43.71% |
| 2015 Q1 | 286.26 Million TWD | 65.86% |
| 2014 Q1 | 301.19 Million TWD | 49.07% |
| 2014 Q2 | 302.57 Million TWD | 0.46% |
| 2014 Q3 | 268.18 Million TWD | -11.37% |
| 2014 Q4 | 172.6 Million TWD | -35.64% |
| 2014 FY | 172.6 Million TWD | -14.57% |
| 2013 Q4 | 202.04 Million TWD | -20.58% |
| 2013 Q1 | - TWD | 0.0% |
| 2013 FY | 202.04 Million TWD | 17.06% |
| 2013 Q3 | 254.4 Million TWD | 0.0% |
| 2012 FY | 172.6 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 605.96 Million TWD | -158.106% |
| Maxigen Biotech Inc. | 50 Thousand TWD | -3127950.0% |
| SciVision Biotech Inc. | 347.91 Million TWD | -349.545% |
| Bionime Corporation | 2.81 Billion TWD | 44.483% |
| Visco Vision Inc. | 1.08 Billion TWD | -44.312% |